Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Income towards Parent Company (2020 - 2023)

Cullinan Therapeutics has reported Income towards Parent Company over the past 4 years, most recently at -$25.6 million for Q4 2023.

  • Quarterly results put Income towards Parent Company at -$25.6 million for Q4 2023, up 5.63% from a year ago — trailing twelve months through Dec 2023 was -$155.1 million (down 242.04% YoY), and the annual figure for FY2025 was -$219.9 million, down 31.21%.
  • Income towards Parent Company for Q4 2023 was -$25.6 million at Cullinan Therapeutics, up from -$39.2 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for CGEM hit a ceiling of $174.1 million in Q2 2022 and a floor of -$58.1 million in Q1 2023.
  • Median Income towards Parent Company over the past 4 years was -$21.6 million (2021), compared with a mean of -$10.8 million.
  • Peak annual rise in Income towards Parent Company hit 1158.85% in 2022, while the deepest fall reached 1008.53% in 2022.
  • Cullinan Therapeutics' Income towards Parent Company stood at -$29.1 million in 2020, then fell by 17.57% to -$34.2 million in 2021, then grew by 20.81% to -$27.1 million in 2022, then increased by 5.63% to -$25.6 million in 2023.
  • The last three reported values for Income towards Parent Company were -$25.6 million (Q4 2023), -$39.2 million (Q3 2023), and -$32.2 million (Q2 2023) per Business Quant data.